Both patients with HFrEF (HR: 0.74, 95% CI: 0.65–0.85, P < 0.001) and HFpEF (HR: 0.82, 95% CI: 0.73–0.92, P = 0.0008) experienced significant decreases in cardiovascular death and HF progression through SGLT2 inhibitors treatment. This evidence concerns the gene SLC5A2 and hydrops fetalis.